+

WO1993019176A1 - Sequences de leucine type zipper - Google Patents

Sequences de leucine type zipper Download PDF

Info

Publication number
WO1993019176A1
WO1993019176A1 PCT/GB1993/000582 GB9300582W WO9319176A1 WO 1993019176 A1 WO1993019176 A1 WO 1993019176A1 GB 9300582 W GB9300582 W GB 9300582W WO 9319176 A1 WO9319176 A1 WO 9319176A1
Authority
WO
WIPO (PCT)
Prior art keywords
myc
max
helix
gene product
polypeptide according
Prior art date
Application number
PCT/GB1993/000582
Other languages
English (en)
Inventor
Karl Hartmut Land
Bruno Bernardo Amati
Original Assignee
Imperial Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929206237A external-priority patent/GB9206237D0/en
Priority claimed from GB929220653A external-priority patent/GB9220653D0/en
Application filed by Imperial Cancer Research Technology Limited filed Critical Imperial Cancer Research Technology Limited
Priority to EP93906719A priority Critical patent/EP0633933A1/fr
Priority to JP5516385A priority patent/JPH07505054A/ja
Publication of WO1993019176A1 publication Critical patent/WO1993019176A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to peptides which inhibit the binding of proteins via helix-loop-helix/leucine zipper domains (HLH-Z) to related products, to processes for their production and their use in medicine.
  • HHL-Z helix-loop-helix/leucine zipper domains
  • the Myc gene product has been associated with a variety of tumours including pro-myelocytic leukaemia, colon carcinomas, large and small cell lung carcinoma and breast carcinoma.
  • the Myc gene product is known to be involved in driving the cell cycle but the mechanism of action has not yet been elucidated.
  • the Myc gene product is also known to contain a HLH-Z motif and to have the ability to bind to DNA.
  • the sequence specific binding of the Myc gene product to DNA was first noted by Blackwell, T.K. et a_l. in 1990 (Science, 2_5_0, 1149-1151) who postulated that this binding might be responsible for some of the biological functions of the Myc gene product.
  • Leucine zippers and helix-loop-helix domains are two classes of peptide sequences each of which permit hetero- or homodimerisation of polypeptide chains by specific interactions, such as that of GCN4 (a leucine zipper protein) , the crystal structure of which has been described by O'Shea, E.K. et al [Science, 254, 539-544 (1991) ] and Myo D, a helix- loop-helix protein (Tapscott, S.J., Science, 24 . 2, 405-411 (1988)) .
  • GCN4 a leucine zipper protein
  • the present inventors have surprisingly established that it is Myc:Max heterodimerisation which leads to the oncogenic effect of Myc and that this interaction can be disrupted by peptides containing an appropriate HLH-Z domain thereby reducing or abolishing the transformation of cells into tumour cells normally associated with overexpression of Myc.
  • the present invention therefore provides polypeptides which specifically bind to the HLH-Z domain of either the Myc gene product or the Max gene product so as to prevent Myc: ax heterodimerisation under physiological conditions.
  • the polypeptides of the invention contain a HLH-Z domain and are capable of specifically binding the HLH-Z domain of either the Myc or the Max gene product. Certain of the polypeptides of the invention will be capable of specifically binding to the HLH-Z domain of the Max gene product. Others will specifically bind to HLH-Z domain of the Myc gene product; these are preferred embodiments of the invention.
  • the sequence of the HLH-Z domains of the Myc and Max gene products have been published by Blackwood et aJL. loc. cit. Binding of a polypeptide to either of these motifs in order to inhibit the Myc:Max heterodimerisation can be tested essentially by the techniques used in Examples 1 and 2 below.
  • polypeptide of the invention will bind only to the HLH-Z domain of the Myc or the Max gene product an will not bind to any other HLH-Z domain under physiological conditions. More preferably the polypeptide of the invention will also be incapable of homodimerisation under physiological conditions.
  • polypeptides of the invention must be sufficiently long that they can adopt a suitable helical conformation for binding to the target sequence.
  • the polypeptides must contain a sufficient number of amino acid residues to permit stable binding to the target sequence.
  • the polypeptide may contain a sequence capable of bindin to the helix-loop-helix domain or to the leucine zipper domain of the Myc or Max gene product.
  • the polypeptides o the invention contain a sequence capable of binding at least the leucine zipper domain of the Myc or Max gene product and more preferably they contain a sequence capable of binding the entire HLH-Z domain of the Myc or Max gene product.
  • the polypeptides of the invention may advantageously contain a sequence capable of binding the B- region of the Myc or Max gene products.
  • polypeptides are therefore likely to contain not less than 7 amino acid residues corresponding with a complete heptad repeat of the leucine zipper domain of the Myc or Max gene product.
  • length of the polypeptides There is no specific upper limit on the length of the polypeptides though economy and other considerations, such as the requirements imposed by likely treatment regimes, will place practical constraints on the length of the polypeptide. It is considered unlikely that the polypeptide would contain more than 500 amino acid residues and the preferred polypeptide will usually be less than 250, for instance less than 100 residues in length.
  • the HLH-Z domains of the Myc and Max gene products are respectively 67 and 66 amino acid residues in length and particularly preferred polypeptides will therefore have a length of up to 90, for instance up to 70, 50, 40, 30 or 20 amino acid residues.
  • the sequence of the polypeptide may be tailored to meet requirements other than specific binding to the HLH-Z domain of the Myc or Max gene products, for instance to satisfy the needs for pharmaceutical acceptability, .in vivo half life and biodegradability.
  • the polypeptides of the invention may also contain sequences unrelated to the function of binding to the HLH-Z domains of the Myc or Max gene products.
  • Preferred polypeptides intended to bind specifically to the HLH-Z domain of the Myc gene product will include the HLH-Z motif, or at least 7 contiguous amino acid residues thereof, of the Max gene product.
  • Preferred polypeptides intended to bind specifically to the HLH-Z domain of the Max gene product will include the HLH-Z motif, or at least 7 contiguous amino acid residues thereof, of the Myc gene product.
  • Other preferred polypeptides are analogues of these in which amino acid residues at particular positions are modified or replaced so as to enhance the affinity of the polypeptide for the target whilst retaining the ability specifically to bind the target HLH-Z domain.
  • modification or replacement will be at one or more residues which appear at the interface between the polypeptide and the target HLH-Z domain of the target protein.
  • polypeptides of the invention are targeted at the HLH-Z domain of the Max gene product and comprise at least 7 amino acid residues of the HLH-Z domain of the Myc gene product or are analogues thereof.
  • the polypeptides of the invention may be produced by conventional techniques either by expression of coding DNA sequences in a cell-free expression system or in host cells containing the necessary regulatory sequences suitably associated with the expressible sequences encoding the polypeptide and cultured under suitable conditions to ensure expression thereof.
  • the methods for expression or synthesis of polypeptides are all well known to those skilled in the art and do not require further description here although reference may be made to Sambrook, J., Fritsch, E.F., Maniatis, T.
  • Treatment may be by administration of an effective non-toxic amount of the polypeptide by any standard route.
  • Oral, topical and parenteral routes are particularly convenient and, particularly for systemic treatment with polypeptides likely to be degraded by passage through the gastro-intestinal tract or unlikely to be absorbed therefrom, parenteral administration, eg intravenous, intra- peritoneal, intramuscular, intradermal or subcutaneous injection or infusion, is preferred.
  • parenteral administration eg intravenous, intra- peritoneal, intramuscular, intradermal or subcutaneous injection or infusion
  • the polypeptide can be produced in situ by expression of suitable coding sequences of DNA or RNA administered for instance as attenuated viruses.
  • the polypeptide will be presented in a suitable pharmaceutical formulation comprising a pharmaceutically acceptable diluent or carrier, e.g.
  • the formulations may be presented as unit or multi-dose forms such as tablets, capsules, creams, lotions, pastes, powders and aqueous solutions, dispersions or suspensions.
  • the formulation is preferably presented as an injectable aqueous solution or suspension or as a lyophilised powder for reconstitution as an aqueous solution or suspension using water for injection, sterile water or pyrogen free water.
  • the polypeptides are targeted to the tumour cells to be treated.
  • the dose of the polypeptide to be administered will depend upon the age, weight, sex and condition of the patient, the size, nature and location(s) of the tumour(s) to be treated and the chosen route of administration. As a general guide each dose may be in the region of from 1 mg to 1 g, for instance 10 mg to 100 mg, preferably about 50 mg of polypeptide.
  • Such doses may be repeated several times per day and for several days, weeks or even months in order to treat the tumours.
  • the daily dose for an average human adult of about 75kg would typically be in the range of from lmg to log, preferably about 50 mg to 2 g.
  • the present invention provides the following:
  • Nucleic acids (DNA or RNA, single or double stranded) having sequences encoding a polypeptide of the invention.
  • Such materials may contain additional coding and/or non- coding sequences, regulatory sequences necessary to secure expression of the coding sequence, markers, ligation and splicing sites, restriction endonuclease cutting and/or recognition sites, and may be circular or linear and in the latter case may have sticky or blunt ends.
  • vectors comprising a nucleic acid as described in (a) .
  • Such vectors may be plasmids, cosmids, viral genomic nucleic acids or yeast artificial chromosomes or other vectors known per s_e.
  • Polypeptides of the invention for use in a method of treatment practised on the human or animal body.
  • composition comprising a polypeptide according to the invention and a diluent or carrier therefor.
  • a method of treatment comprising administering a polypeptide of the invention or a pharmaceutical composition comprising a polypeptide of the invention and a diluent or carrier therefor to a human or animal having a tumour associated with overexpression of the Myc gene product.
  • a process for screening candidate therapeutic agents intended to interfere with Myc: Max heterodimerisation comprises contacting cells with the candidate therapeutic agents or, when the candidate therapeutic agent is a peptide, optionally expressing the peptide in the cells, which cells contain a reporter gene the expression of which is enhanced or reduced by agents which interfere with Myc:Max heterodimerisation, and observing the level of expression of the reporter gene by the cells.
  • peptides which are candidate therapeutic agents are expressed in cells whic also express (a) either (but not both) of Myc or a Max construct also containing a transcription activation domain and (b) a reporter gene regulated by the transcription activation domain of Myc or the Max construct.
  • a library of constructs encoding candidate peptides is expressed.
  • Candidates for further evaluation are selected on the basis of good levels of expression of the reporter gene resulting from heterodimerisation of the peptide with the expressed Myc or Max construct.
  • the cells used do not expres Myc or Max from homologous DNA.
  • candidate therapeutic agents are screened for their ability to abolish expression of a reporter gene regulated by Myc: Max heterodimerisation in cells which, preferably, express Myc or Max only from heterologous DNA.
  • This technique may be used for screening peptides expressed in the cells from heterologous DNA or for screening any candidate agent, whether or not a peptide, for instance a synthetic peptide analogue which can be administered to the cells.
  • the cells used in this screening technique are yeast cells and the screening is conducted by conventional methods such as those of Examples 1 and 2.
  • the present invention will now be illustrated by reference to the figures of the drawings in which
  • Fig. 1 shows in diagrammatic form the various domains of the Myc and Max gene products and the Myc 92 polypeptide of the invention.
  • Fig. 2 shows the nucleotide sequence of double stranded DNA encoding the Myc 92 polypeptide of the invention and the amino acid residue sequence of Myc 92 polypeptide.
  • Fig. 3 is a schematic representation of human c-Myc, Max and Max deletion derivatives and of the CACGTG-CYCl-LacZ reporter gene used in Example 2.
  • Fig. 4 shows levels of activation by Myc and Max in yeast cells.
  • Fig. 5 gives a schematic representation of certain fusion proteins and shows levels of activation in yeast cells.
  • Fig. 6 is a diagram illustrating Myc and Max interactions and function.
  • Fig. 1 the basic (B) and helix-loop-helix (HLH) and leucine zipper (LZ) domains of the Myc and Max gene products are shown together with amino acid residue numbers for the boundaries between the domains.
  • the Myc and Max gene products are shown aligned with the Myc92 polypeptide which inhibits Myc:Max heterodimerisation.
  • Fig. 2 the amino acid residue sequence of the Myc 92 polypeptide is shown with residues numbered according to the corresponding positions of the amino acid residues in the full length Myc protein. A double stranded DNA sequence encoding the Myc 92 polypeptide is also shown. The internationally recognised 1-letter codes are used for both the nucleotide bases and the amino acid residues.
  • Example 1 The invention is further illustrated by the following Examples, which should not be taken as limiting the invention in any way.
  • Example 1
  • a polypeptide, Myc 92 (see Fig.l), containing a sequence corresponding to the B-HLH-Z domain of the Myc gene product wa co-expressed with the Myc and Ras oncoproteins in rat embryo cells (REC) by the same methodology as described for co- expression of the Myc and Ras oncoproteins [Land, H. et al. , Nature, 304, 596-602(1983)]. Whereas co-expression of only the Myc and Ras oncoproteins in REC leads to malignant transformation of the cells, this activity is suppressed when Myc 92 is also expressed. This occurs through competition with Myc for the interaction with cellular Max protein. EXAMPLE 2
  • the C-Myc protein contains an amino-terminal transcriptional activation domain 1 and a carboxyl-terminal basic/helix-loop-helix/leucine zipper (bHLH-Z) domain 2"5 which directs dimerisation of Myc with its partner Max and DNA binding to sites containing a CACGTG core consensus 6'9 .
  • Myc can modulate gene expression "0-10 , a direct role for Myc or Max as transcription factors has never been demonstrated.
  • Saccharo yces cerevisiae as an in vivo model system we show that the Myc protein is a sequence-specific transcriptional activator whose DNA_ binding is strictly dependent on dimerisation with Max.
  • Transactivation is mediated by the amino-terminal domain of Myc.
  • Max homodimers bind to the same DNA sequence as Myc/Max but fail to transactivate in our assays and thus can antagonise Myc/Max function.
  • Max HLH-Z domain has a higher affinity for the Myc HLH-Z domain than for itself and suggest that the heterodimeric Myc/Max activator forms preferentially at equilibrium.
  • VPl6-Myc ⁇ N (retaining Myc res. 180-439) transactivates only when co-expressed with Max. This is consistent with the idea that DNA binding and therefor transactivation by Myc requires association with Max (either Maxl or Max2) or at least the Max bHLH-Z domain (Max85, Figs. and 4a) , although an involvement of related yeast proteins 11 in the observed effects cannot be ruled out.
  • Max either Maxl or Max2
  • MaxbHLH-Z domain Max85, Figs. and 4a
  • Maxl03-VP16 by itself transactivates the CACGTG-CYC1 promoter (Fig. 4b) .
  • Max can bind DNA in the absence of Myc but does not significantly activate transcription in our system unless tagged with a heterologous transactivation domain.
  • Max proteins tested bind DNA as homo-oligomers in yeast extracts (ref. 9 and data not shown) , as recently reported for bacterially expressed Max 12,13 .
  • Transactivation of the CACGTG-CYCl promoter is sequence- specific, since much less or no transactivation by Myc/Max (Fig. 4a, lanes a) , VP16-Myc ⁇ N/Ma or Maxl03-VP16 (Fig. 4b) is observed from a control reporter lacking the CACGTG binding site (see also Fig. 4a, legend) .
  • Max/Max dimers Because of their apparent lack of transcriptional activity, we expected Max/Max dimers to antagonise transactivation by Myc/Max through competition for the same DNA target sites. Consistent with this idea, introducing an additional Max plasmid into the cells leads to a reduction of transactivation by Myc/Max or Myc/Max85 (Fig. 4c) . On the other hand, introduction of an additional Myc plasmid enhances transactivation levels in the presence of Max or Max85 (Fig. 4c) , supporting the conclusion that Myc provides the activation domain. Thus, the activities of different Myc/Max dimers primarily reflect the equilibrium between Myc/Max and Max/Max complexes rather than their absolute efficiencies (Fig. 4, see also legend) .
  • Max ⁇ C and Max85 proteins seem to allow better Myc/Max function than full-length Max (Fig. 4a) , while all Max proteins were expressed at similar levels (not shown) .
  • Both truncated proteins lack the carboxyl-terminal nuclear import sequence 12 - 14 and may therefore be less effective as homodimeric competitors, while the respective heterodimers with Myc are efficiently transported into the nucleus 14 .
  • the functional domains of Myc were analysed by measuring the dimerisation of various Myc mutants with SRF-Max72 and their DNA binding properties together with Max (Fig. 5c) . Mutants in the basic region (360N/P and 364,6,7R/A) are unable to transactivate the CACGTG reporter but retain dimerisation activity. Thus, similar to other bHLH proteins 20-21 , the basic region of Myc is essential for DNA binding but dispensable for dimerisation which is mediated by the HLH-Z domain alone (Fig. 5b) . Consistent with this idea, deletions of either HLH or LZ domains of Myc did not show any activity, although no positive controls are available for these mutants (not shown) .
  • the transactivation domain of Myc maps to the 177 amino-terminal residues, consistent with the mapping of this domain in GAL4- Myc chimaeras in mammalian cells 1 .
  • the deletion mutant Myc ⁇ N (retaining residues 178 to 439) fails to activate both in dimerisation and DNA binding assays (Fig. 5c) , but efficiently enhances transactivation by Max-VP16 (Fig. 3c) . This shows that Myc ⁇ N can dimerise and bind DNA but does not transactivate.
  • the Myc transactivation domain also functions in yeast when fused to heterologous DNA binding domains (LexA- Myc 22 and l-235Myc-SRF, not shown) .
  • FIGURE LEGENDS Fig. 3 Schematic representation of human c-Myc, Max, and Max deletion derivatives, and of the CACGTG-CYCl-LacZ reporter gene used in this study.
  • the bHLH-Z domains of Myc and Max are aligned.
  • Maxl and Max2 are the natural Max variants without and with the 9 amino acid insert, respectively 7 .
  • the Max ⁇ C and Max85 mutants are truncated at the position in Max equivalent to the Myc carboxyl-terminus.
  • Max2, Maxl ⁇ C, Max2 ⁇ C, and Max85 were generated by PCR with appropriate primers from a Maxl cDNA template (a gift from D. Gillespie) . All the coding regions were subcloned into galactose-inducible CEN-ARS plasmids of the pSD series of yeast expression vectors 15 , with either TRP1, LEU2 or HIS3 as selective markers. Due to usage of the CYC1 ATG initiation codon the following amino-terminal extensions precede the proteins: MTGFPGLQEFELAPTM (Myc), MTGFELE (Maxl and Maxl03-VP16 see Fig.
  • Fig. 4 Transcriptional activation by Myc and Max in yeast.
  • CACATG is the only half-site change permitting DNA binding by Myc/Max, Maxl or Max2 , albeit with decreased affinity (ref. 12, D. Solomon, B.A. and H.L. , unpublished data) . Since all Max proteins were expressed at similar levels, the relatively higher efficiencies of Myc with Max2 , Max2 ⁇ C or Max85, compared with Maxl or Maxl ⁇ C, may in part be due to differences in affinity for DNA (ref.
  • b Transactivation by VPl6-Myc ⁇ N and Maxl03-VP16 together with Max or Myc ⁇ N. Note that VP16-Myc ⁇ N and Maxl03-VP16 activities cannot be directly compared, since their relative expression levels are unknown.
  • c Effect of a third Myc or Max plasmid on transactivation of the CACGTG reporter. Myc plasmids with different genetic markers than in (a) were used for Myc+Max and Myc+Max85 (LEU2 in a, HIS3 in 3 ) .
  • Maxl03-VP16 was constructed by replacing Max sequences 3' of codon 103 with a VP16 fragment (residues 410- 490) from pSD.06a (ref. 15) .
  • VP16-Myc ⁇ N contains the VP16 fragment upstream of Myc codons 180 to 439. Myc ⁇ N retains codons 178 to 439.
  • Myc and Max plasmids were transformed into the ho ura3 his 3 trpl ade2 leu2 canl-100 yeast strain W303-1B (MAT ⁇ ) , and reporter plasmids into the isogenic strain W303-1A (MATa) . Protein/reporter combinations were generated by crossing transformants.
  • Fig. 5 Myc/Max interactions in vivo .
  • a Assay for interactions between Myc and Max HLH-Z domains. In this assay 15 activation of the SRE-LacZ reporter gene is strictly dependent on the interaction in trans between chimaeric proteins containing the SRF DNA-binding and the VP16 transactivation domains, respectively.
  • a schematic representation of the fusion proteins and the reporter gene used is given.
  • the SRE- CYCl-LacZ reporter gene is integrated into the genome of the indicator yeast strain S62L, (ref. 15.)
  • b Relative B- galactosidase units (as defined in Fig. 4) in S62L cells expressing the indicated proteins.
  • Myc92, Myc73, and Max72-encoding DNA fragments were 'generated by PCR and subcloned in frame downstream of VP16 or SRF412 (residues 1-412 of SRF) in vectors pSD.06a and pSD.08, respectively 15 .
  • SRF412 alone was expressed from a modified version of pSD.08.
  • Myc point mutants were generated by site- directed mutagensis using standard methods. The reading frame of all fusions, the point mutations and all the PCR-generated inserts were verified by DNA sequencing.
  • Fig.6 Schematic summary of Myc and Max interaction and function.
  • Myc and Max form stable heterodimers in the absence of DNA (in solution) .
  • Weak Max/Max interactions can also be detected, but Myc/Myc homodimers do not form at physiological concentrations in vitro or in vivo .
  • Both Myc/Max and Max/Max bind to the same DNA sequence.
  • only the Myc/Max heterodimer detectably functions as a sequence-specific transcriptional activator in yeast.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Polypeptide se liant spécifiquement au domaine de leucine type zipper/d'hélice-boucle-hélice du produit du gène Myc ou du produit du gène Max de façon à prévenir l'hétérodimérisation Myc:Max dans des conditions physiologiques. Ces polypeptides peuvent être utilisés dans le cadre d'applications diagnostiques et thérapeutiques se rapportant aux tumeurs associées à une surexpression du produit du gène Myc. Des agents thérapeutiques potentiels peuvent être triés selon un procédé qui consiste à mettre des cellules en contact avec les agents thérapeutiques potentiels, ou, lorsque cet agent potentiel est un peptide, à exprimer éventuellement le peptide dans les cellules, celles-ci contenant un gène rapporteur dont l'expression est favorisée ou réduite par des agents agissant sur l'hétérodimérisation Myc:Max, et à observer le niveau d'expression du gène rapporteur par les cellules.
PCT/GB1993/000582 1992-03-23 1993-03-22 Sequences de leucine type zipper WO1993019176A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP93906719A EP0633933A1 (fr) 1992-03-23 1993-03-22 Sequences de leucine type zipper
JP5516385A JPH07505054A (ja) 1992-03-23 1993-03-22 ロイシンジッパー

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206237A GB9206237D0 (en) 1992-03-23 1992-03-23 Leucine zippers
GB9206237.1 1992-03-23
GB929220653A GB9220653D0 (en) 1992-09-30 1992-09-30 Leucine zippers
GB9220653.1 1992-09-30

Publications (1)

Publication Number Publication Date
WO1993019176A1 true WO1993019176A1 (fr) 1993-09-30

Family

ID=26300573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000582 WO1993019176A1 (fr) 1992-03-23 1993-03-22 Sequences de leucine type zipper

Country Status (3)

Country Link
EP (1) EP0633933A1 (fr)
JP (1) JPH07505054A (fr)
WO (1) WO1993019176A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708653A1 (fr) * 1993-06-04 1996-05-01 Mitotix, Inc. Techniques et reactifs utilises pour l'identification d'agents antiproliferatifs
WO1997040379A2 (fr) * 1996-04-23 1997-10-30 Cold Spring Harbor Laboratory EPREUVES ET REACTIFS PERMETTANT L'IDENTIFICATION DE MODULATEURS D'ACTIVATION DE LA MITOSE INDUITE PAR Cdc25
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO2001072785A1 (fr) * 2000-03-17 2001-10-04 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine helice-boucle-helice 17 (b-hlh), et polynucleotide codant pour ce polypeptide
WO2010034031A1 (fr) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
US9074009B2 (en) 2006-11-15 2015-07-07 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
KR20160013058A (ko) * 2013-05-07 2016-02-03 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 디 발 드헤브론 (브이에이치아이오) 암의 치료를 위한 방법 및 조성물
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016456A1 (fr) * 1990-04-19 1991-10-31 The General Hospital Corporation Techniques de triage de composes inhibant la liaison de c-myc a l'adn
WO1993005056A1 (fr) * 1991-09-09 1993-03-18 Fred Hutchinson Cancer Research Center Proteine zip helice-boucle-helice max:a, formant avec les polypeptides myc et mad un complexe de liaison d'adn specifique de la sequence

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016456A1 (fr) * 1990-04-19 1991-10-31 The General Hospital Corporation Techniques de triage de composes inhibant la liaison de c-myc a l'adn
WO1993005056A1 (fr) * 1991-09-09 1993-03-18 Fred Hutchinson Cancer Research Center Proteine zip helice-boucle-helice max:a, formant avec les polypeptides myc et mad un complexe de liaison d'adn specifique de la sequence

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL vol. 65, 1991, pages 395395 - 407 G.C. PRENDERGAST ET AL.; 'Association of myn, the murine homolog of max, with c-myc stimulates methylation-sensitive DNA binding and ras cotransformation' *
CHEMICAL ABSTRACTS, vol. 116, no. 23, 1992, Columbus, Ohio, US; abstract no. 232515p, E.M. BLACKWOOD ET AL.; 'Myc and max associate in vivo' *
CHEMICAL ABSTRACTS, vol. 118, no. 13, 1993, Columbus, Ohio, US; abstract no. 122015j, B. AMATI ET AL.; 'Oncogenic activity of the c-myc protein requires dimerization with max' *
SCIENCE vol. 251, 1991, E.M. BLACKWOOD ET AL.; 'Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc' *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
EP0708653A1 (fr) * 1993-06-04 1996-05-01 Mitotix, Inc. Techniques et reactifs utilises pour l'identification d'agents antiproliferatifs
EP0708653A4 (fr) * 1993-06-04 1998-11-18 Mitotix Inc Techniques et reactifs utilises pour l'identification d'agents antiproliferatifs
US6251585B1 (en) 1993-06-04 2001-06-26 Mitotix, Inc. Assay and reagents for identifying anti-proliferative agents
WO1997040379A2 (fr) * 1996-04-23 1997-10-30 Cold Spring Harbor Laboratory EPREUVES ET REACTIFS PERMETTANT L'IDENTIFICATION DE MODULATEURS D'ACTIVATION DE LA MITOSE INDUITE PAR Cdc25
WO1997040379A3 (fr) * 1996-04-23 1998-01-29 Cold Spring Harbor Lab EPREUVES ET REACTIFS PERMETTANT L'IDENTIFICATION DE MODULATEURS D'ACTIVATION DE LA MITOSE INDUITE PAR Cdc25
WO2001072785A1 (fr) * 2000-03-17 2001-10-04 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine helice-boucle-helice 17 (b-hlh), et polynucleotide codant pour ce polypeptide
US9074009B2 (en) 2006-11-15 2015-07-07 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
WO2010034031A1 (fr) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10022422B2 (en) 2009-01-14 2018-07-17 Alleron Therapeutics, Inc. Peptidomimetic macrocycles
KR20160013058A (ko) * 2013-05-07 2016-02-03 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 디 발 드헤브론 (브이에이치아이오) 암의 치료를 위한 방법 및 조성물
US10370434B2 (en) 2013-05-07 2019-08-06 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Methods and compositions for the treatment of cancer
KR102324116B1 (ko) 2013-05-07 2021-11-11 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 암의 치료를 위한 방법 및 조성물
US11339205B2 (en) 2013-05-07 2022-05-24 Fundació Privada Institut D'investigació Methods and compositions for the treatment of cancer
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Also Published As

Publication number Publication date
EP0633933A1 (fr) 1995-01-18
JPH07505054A (ja) 1995-06-08

Similar Documents

Publication Publication Date Title
US20200164035A1 (en) Methods of using variants of fgf19 polypeptides for the treatment of cancer
Madaule et al. A novel partner for the GTP‐bound forms of rho and rac
Abarzúa et al. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53
Swirnoff et al. Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain
Bengal et al. Functional antagonism between c-Jun and MyoD proteins: a direct physical association
RU2584579C2 (ru) Способы лечения злокачественной опухоли с использованием ингибиторов пути передачи сигнала notch
Rafty et al. Sp1 phosphorylation regulates inducible expression of platelet-derived growth factor B-chain gene via atypical protein kinase C-ζ
KR20060054196A (ko) 전달가능한 ｄｎａ-결합 단백질
WO1996020954A2 (fr) Domaines fonctionnellement actifs de proteines transducteurs de signaux et activateurs de transcription (stat)
JP2001514007A (ja) キメラ転写アクチベーター、ならびにそれに関連する組成物および使用
CN111655277B (zh) Atf5肽变体及其用途
EP0808630A1 (fr) Traitement du cancer
WO1993019176A1 (fr) Sequences de leucine type zipper
AU731431B2 (en) Materials and methods relating to inhibiting the interaction of p53 and mdm2
Shnyreva et al. The oncoprotein Tax of the human T-cell leukemia virus type 1 activates transcription via interaction with cellular ATF-1/CREB factors in Saccharomyces cerevisiae
Musso et al. An upstream positive regulatory element in human GM-CSF promoter is recognized by NF-κB/Rel family members
Fujimoto et al. Novel isoforms of human cyclic AMP-responsive element modulator (hCREM) mRNA
US20030148954A1 (en) Agents and methods for modulating activator protein-1-mediated cellular processes
US5688918A (en) p53as protein and antibody therefor
EP2429563B1 (fr) Peptide perturbant le complexe protéique entre la protéine p53 mutée his273 et la protéine oncosuppressive p73 dans des cellules tumorales et ses utilisations thérapeutiques
BG63548B1 (bg) Полипептиди, съдържащи протеинови домени на gax, включени в транскрипцията и/или взаимнодействащи сдруги протеини, съответни нуклеинови киселини и тяхното използване
WO2004016646A2 (fr) Modulateurs peptidiques d'un sous-type de pyruvate kinase m2 (m2-pk) specifique de tumeurs
Milbrandt et al. Nab1, a Corepressor of NGFI-A (Egr-1)
Human CREB-2, a Cellular CRE-Dependent
Collum Studies on the structure and function of N-myc

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 307726

Date of ref document: 19940923

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1993906719

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993906719

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993906719

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载